Does GLP-1 suppress hepatocyte glucose production directly, via fibroblast growth factor 21?
作者信息
Liu Jun-Li, Gao Zu-Hua
机构信息
Departments of Medicine and Pathology, Research Institute of McGill University Health Center, Montreal, Quebec, Canada.
出版信息
EBioMedicine. 2019 Mar;41:5-6. doi: 10.1016/j.ebiom.2019.03.012. Epub 2019 Mar 12.
Abstract
摘要
相似文献
1
Does GLP-1 suppress hepatocyte glucose production directly, via fibroblast growth factor 21?胰高血糖素样肽-1是否通过成纤维细胞生长因子21直接抑制肝细胞葡萄糖生成？
EBioMedicine. 2019 Mar;41:5-6. doi: 10.1016/j.ebiom.2019.03.012. Epub 2019 Mar 12.
2
Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output.肝源成纤维细胞生长因子 21 介导胰高血糖素样肽-1 减轻肝葡萄糖输出的作用。
EBioMedicine. 2019 Mar;41:73-84. doi: 10.1016/j.ebiom.2019.02.037. Epub 2019 Mar 1.
3
Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice.工程化的产生胰高血糖素样肽-1的肝细胞可降低小鼠的血糖水平。
Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E936-44. doi: 10.1152/ajpendo.90768.2008. Epub 2009 Feb 3.
4
GLP-1 (9-36) amide metabolite suppression of glucose production in isolated mouse hepatocytes.GLP-1(9-36)酰胺代谢物抑制分离的小鼠肝细胞的葡萄糖生成。
Horm Metab Res. 2010 Aug;42(9):657-62. doi: 10.1055/s-0030-1253421. Epub 2010 May 28.
5
Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice.成纤维细胞生长因子 21（FGF21）和胰高血糖素样肽 1 有助于缺乏胰高血糖素受体的小鼠抵抗糖尿病。
Diabetes. 2014 Jan;63(1):101-10. doi: 10.2337/db13-0710. Epub 2013 Sep 23.
6
GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes.胰高血糖素样肽-1（GLP-1）衍生的九肽GLP-1(28 - 36)酰胺作用于线粒体，并抑制分离的小鼠肝细胞中的葡萄糖生成和氧化应激。
Regul Pept. 2011 Apr 11;167(2-3):177-84. doi: 10.1016/j.regpep.2011.01.003. Epub 2011 Jan 21.
7
Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer.胆汁酸螯合剂司维拉姆的降糖作用及机制
Diabetes Obes Metab. 2018 Jul;20(7):1623-1631. doi: 10.1111/dom.13272. Epub 2018 Mar 26.
8
GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats.胰高血糖素样肽-1对糖尿病大鼠脂肪细胞和肝细胞中糖基磷脂酰肌醇/胰岛素蛋白酶抑制蛋白系统的影响。
Diabetes Nutr Metab. 2001 Oct;14(5):239-44.
9
Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes.解锁胰高血糖素样肽-1类似物与成纤维细胞生长因子21联合用药对2型糖尿病动脉粥样硬化发病机制的治疗潜力。
Endocrinol Metab (Seoul). 2021 Feb;36(1):57-59. doi: 10.3803/EnM.2021.109. Epub 2021 Feb 24.
10
Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?治疗糖尿病的药物胰高血糖素样肽-1会是阿尔茨海默病的新希望吗？
Neurosci Bull. 2007 Jan;23(1):58-65. doi: 10.1007/s12264-007-0009-y.
引用本文的文献
1
The impact of glucagon to support postabsorptive glucose flux and glycemia in healthy rats and its attenuation in male Zucker diabetic fatty rats.胰高血糖素对健康大鼠餐后葡萄糖流和血糖的影响及其在雄性 Zucker 糖尿病肥胖大鼠中的减弱作用。
Am J Physiol Endocrinol Metab. 2024 Mar 1;326(3):E308-E325. doi: 10.1152/ajpendo.00192.2023. Epub 2024 Jan 24.
2
Short-term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice.短期司美格鲁肽治疗可改善高脂肪饮食挑战小鼠原代肝细胞中 FGF21 的反应性。
Physiol Rep. 2023 Mar;11(5):e15620. doi: 10.14814/phy2.15620.
3
Hepatic hormone FGF21 and its analogues in clinical trials.肝脏激素FGF21及其类似物的临床试验
Chronic Dis Transl Med. 2022 Feb 23;8(1):19-25. doi: 10.1016/j.cdtm.2021.08.005. eCollection 2022 Mar.
本文引用的文献
1
Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output.肝源成纤维细胞生长因子 21 介导胰高血糖素样肽-1 减轻肝葡萄糖输出的作用。
EBioMedicine. 2019 Mar;41:73-84. doi: 10.1016/j.ebiom.2019.02.037. Epub 2019 Mar 1.
2
A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21.十二年的探索：成纤维细胞生长因子 21 的生理学和药理学研究进展
Cell Metab. 2019 Feb 5;29(2):246-253. doi: 10.1016/j.cmet.2019.01.004.
3
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.胰高血糖素样肽-1 的作用机制与治疗应用。
Cell Metab. 2018 Apr 3;27(4):740-756. doi: 10.1016/j.cmet.2018.03.001.
4
Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives.胰高血糖素样肽-1及其相关药物的肝脏功能：当前的争议与展望
Am J Physiol Endocrinol Metab. 2016 Sep 1;311(3):E620-7. doi: 10.1152/ajpendo.00069.2016. Epub 2016 Aug 9.
5
Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus.艾塞那肽治疗可降低新诊断2型糖尿病患者的空腹成纤维细胞生长因子21水平。
Diabetes Metab. 2016 Nov;42(5):358-363. doi: 10.1016/j.diabet.2016.04.005. Epub 2016 May 10.
6
FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases.成纤维细胞生长因子21作为一种肝脏因子、脂肪因子和肌肉因子在代谢及疾病中的作用
Front Endocrinol (Lausanne). 2014 Jul 7;5:107. doi: 10.3389/fendo.2014.00107. eCollection 2014.
7
Metabolic actions of fibroblast growth factor 21.成纤维细胞生长因子 21 的代谢作用。
Curr Opin Pediatr. 2012 Aug;24(4):523-9. doi: 10.1097/MOP.0b013e3283557d22.
8
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.长效胰高血糖素样肽-1类似物利拉鲁肽（NN2211）每日一次治疗2型糖尿病患者可改善血糖控制且不增加体重：一项为期12周的双盲、随机、对照试验。
Diabetes Care. 2004 Jun;27(6):1335-42. doi: 10.2337/diacare.27.6.1335.
9
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.合成艾塞那肽-4（艾塞那肽）可显著降低2型糖尿病患者的餐后和空腹血糖水平。
J Clin Endocrinol Metab. 2003 Jul;88(7):3082-9. doi: 10.1210/jc.2002-021545.
Zotero 插件